|
Oct 10
|
Evolus' (NASDAQ:EOLS) investors will be pleased with their solid 119% return over the last three years
|
|
Oct 9
|
Evolus Inc (EOLS) Q2 2024 Earnings Call Highlights: Strong Revenue Growth and Strategic Advancements
|
|
Jul 30
|
Evolus Expands Global Footprint with Introduction of Nuceiva® (botulinum toxin type A) in Australia
|
|
Jul 25
|
Evolus to Participate in the Canaccord Genuity 44th Annual Growth Conference
|
|
Jul 23
|
Evolus’s ‘frown line’ treatment Jeuveau could threaten Botox revenues
|
|
Jul 17
|
Evolus to Report Second Quarter Financial Results on July 31, 2024
|
|
Jun 24
|
Evolus Announces Submission of Premarket Approval Application to the U.S. Food and Drug Administration for First Two Evolysse™ Dermal Filler Products
|
|
Jun 19
|
Market Sentiment Around Loss-Making Evolus, Inc. (NASDAQ:EOLS)
|
|
May 15
|
Evolus Celebrates Fifth Anniversary of Launching its Flagship Product Jeuveau® at the Women’s Wear Daily Beauty CEO Summit
|
|
May 10
|
Evolus’ Sandra Beaver Named Orange County Business Journal’s Public Company CFO of the Year
|
|
May 9
|
Evolus First Quarter 2024 Earnings: Revenues Beat Expectations, EPS Lags
|
|
May 8
|
Evolus, Inc. (NASDAQ:EOLS) Q1 2024 Earnings Call Transcript
|
|
May 8
|
Q1 2024 Evolus Inc Earnings Call
|
|
May 8
|
Evolus Inc (EOLS) (Q1 2024) Earnings Call Transcript Highlights: Strong Growth and Strategic ...
|
|
May 7
|
Evolus, Inc. (EOLS) Reports Q1 Loss, Tops Revenue Estimates
|
|
May 7
|
Evolus Inc (EOLS) Q1 2024 Earnings: Surpasses Revenue Estimates with Significant Growth
|
|
May 7
|
Evolus Reports First Quarter 2024 Results and Provides Business Update
|
|
May 3
|
The 15% return this week takes Evolus' (NASDAQ:EOLS) shareholders one-year gains to 59%
|
|
May 1
|
Green Thumb Industries Inc. (GTBIF) Surges 22.3%: Is This an Indication of Further Gains?
|
|
Apr 23
|
Evolus to Report First Quarter Financial Results on May 7, 2024
|